secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001140361-26-006721
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore reports Q4 2025 KIMMTRAK sales of $104.5M, FY $400M; TEBE-AM data 2H 2026
--------------------------------------------------------------------------------

- Q4 2025 KIMMTRAK net sales $104.5M (+24% YoY); FY2025 $400.0M (+29% YoY).
- FY2025 net loss narrowed to $35.5M from $51.1M in 2024; cash $864.2M.
- R&D spend rose to $274.9M (FY2025) on autoimmune programs and Phase 3 trials.
- TEBE-AM Phase 3 enrollment complete 1H 2026; topline OS data expected 2H 2026.
- PRAME and HIV clinical data presentations expected 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036126006721/0001140361-26-006721-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036126006721/ef20066378_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-006721

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer